NERV - Minerva Neurosciences, Inc.
| Previous Close | 8.07 |
| Open | 8.10 |
| Bid | 7.80 x 1000 |
| Ask | 8.10 x 1800 |
| Day's Range | 7.91 - 8.28 |
| 52 Week Range | 4.07 - 12.95 |
| Volume | 295,532 |
| Avg. Volume | 798,961 |
| Market Cap | 312.204M |
| Beta (3Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.38 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.75 |
- Simply Wall St.
What Kind Of Shareholder Appears On The Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Shareholder Register?
Every investor in Minerva Neurosciences, Inc. (NASDAQ:NERV) should be aware of the most powerful shareholder groups...
- Thomson Reuters StreetEvents
Edited Transcript of NERV earnings conference call or presentation 5-Aug-19 12:30pm GMT
Q2 2019 Minerva Neurosciences Inc Earnings Call
Motley FoolMinerva Neurosciences, Inc. (NERV) Q2 2019 Earnings Call Transcript
NERV earnings call for the period ending June 30, 2019.
- GlobeNewswire
Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in.
- GlobeNewswire
Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019
WALTHAM, Mass., July 29, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central.
- Simply Wall St.
Did Minerva Neurosciences, Inc. (NASDAQ:NERV) Insiders Buy Up More Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- Insider Monkey
Is Minerva Neurosciences, Inc (NERV) A Good Stock To Buy?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
- Benzinga
Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial
Shares of thinly traded micro-cap biotech Minerva Neurosciences Inc (NASDAQ: NERV ) spiked higher on Monday. What Happened Minerva announced results of a Phase 2b study that evaluated its seltorexant, ...
- MarketWatch
UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals
Minerva Neurosciences Inc. shares soared 34% in premarket trade Monday, after the company said its trial of Seltorexant as a treatment for insomnia met its primary and key secondary goals. The company said the Phase 2b trial of the drug met its primary endpoint of latency to persistent sleep, or LPS, at Night 1 in 10 mg and 20 mg doses of Seltorexant. It also met its key secondary endpoint, defined as wake after sleep onset over first 6 hours at Night 1. The beneficial effects were maintained over time and were consistent in adults and elderly patients. "The findings from this study demonstrate that seltorexant significantly improves sleep induction and prolongs sleep duration," said Professor Thomas Roth, Director of the Sleep Disorders and Research Center at Henry Ford Hospital. "The results also demonstrate that seltorexant showed a significantly greater improvement in these sleep parameters compared to zolpidem." The study involved 365 patients with a mean age of 57.8, ranging from 22 to 84 years of age. Minerva shares have fallen 37.2% in 2019 through Friday, while the S&P 500 has gained 17.7%.
- GlobeNewswire
Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced results of a clinical trial (ISM2005) of seltorexant (MIN-202) in patients with insomnia disorder that demonstrated highly statistically significant (p ≤0.001) and clinically meaningful improvement on LPS at Night 1, the primary endpoint of the study. The mean decrease from baseline at Night 1 in LPS was 15 minutes for placebo, 30 minutes for seltorexant 5 mg, 50 minutes for seltorexant 10 mg, and 48 minutes for seltorexant 20 mg.
- GlobeNewswire
Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, will host a live conference call and webcast tomorrow, June 24, 2019 to discuss the results of its successful Phase 2b clinical trial of seltorexant (MIN-202) in patients with insomnia disorder (see dial-in information below). The Company plans to issue a press release detailing top-line results prior to the call.
- GlobeNewswire
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
WALTHAM, Mass., June 12, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to.
- GlobeNewswire
Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019
WALTHAM, Mass., May 29, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to.
- Benzinga
Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug
The drug was evaluated in adult patients with major depressive disorder who have responded inadequately to selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
- GlobeNewswire
Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced positive results from a Phase 2b clinical trial of seltorexant (MIN-202) as adjunctive therapy to antidepressants in adult patients with major depressive disorder (MDD) who have responded inadequately to selective serotonin reuptake inhibitors (SSRIs) and/or serotonin-norepinephrine reuptake inhibitors (SNRIs). In this dose finding study, the 20 milligram (mg) dose of seltorexant, under co-development with Janssen Pharmaceutica NV, showed a statistically significant improvement in the MADRS (Montgomery-Asberg Depression Rating Scale) score compared to placebo.
- Thomson Reuters StreetEvents
Edited Transcript of NERV earnings conference call or presentation 6-May-19 12:30pm GMT
Q1 2019 Minerva Neurosciences Inc Earnings Call
- Simply Wall St.
Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV)
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the May share price for Minerva Neurosciences, Inc. (NASDAQ:NERV) reflect what it's really worth...
- Motley Fool
Minerva Neurosciences, Inc. (NERV) Q1 2019 Earnings Call Transcript
NERV earnings call for the period ending March 31, 2019.
- Associated Press
Minerva Neurosciences: 1Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 41 cents per share. Minerva Neurosciences shares have increased 12% since the beginning of the year. The stock has risen 22% in the last 12 ...
- GlobeNewswire
Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
WALTHAM, Mass., May 06, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central.
- GlobeNewswire
Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
WALTHAM, Mass., April 29, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat.
- GlobeNewswire
Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the presentation of a poster at the 2019 Congress of the Schizophrenia International Research Society in Orlando, Florida entitled Roluperidone increases in-vitro Brain-Derived Neurotrophic Factor (BDNF) release: a possible mechanistic role in negative symptoms? Findings to be presented in Poster #T145 during Poster Session 1 on April 11, 2019, 12:00 p.m. – 2:00 p.m., demonstrate that administration of roluperidone significantly increased BDNF release by astrocytes and hippocampal neurons obtained from the cerebral cortex of newborn rats, as well as the release of GDNF (Glial cell derived neurotrophic factor) in cultured astrocytes. Furthermore, data showed that roluperidone enhanced BDNF gene expression at drug concentrations similar to those observed in humans at tested doses.
- Thomson Reuters StreetEvents
Edited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMT
Q4 2018 Minerva Neurosciences Inc Earnings Call
- GlobeNewswire
Minerva Neurosciences to Host Webcast Event on Schizophrenia
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a webcast, “Schizophrenia: Disease Landscape and Forecast,” on Thursday, March 21, 2019 beginning at 10:00 a.m. eastern time in Boston, MA. Minerva’s Executive Chairman and Chief Executive Officer, Remy Luthringer, Ph.D., will be joined by representatives from Decision Resources Group, a global information and technology services company providing proprietary data and solutions to the healthcare industry, and Dr. Gregory Strauss, an expert key opinion leader.
Motley FoolMinerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript
NERV earnings call for the period ending December 31, 2018.
